Product logins

Find logins to all Clarivate products below.


The 2014 multiple myeloma market garnered impressive sales despite its relatively low incidence compared with other oncology markets with similar revenues. Significant achievements in clinical practice over the last decade and the launches of efficacious, premium-priced agents are set to drive market expansion through 2024. Despite these advances, untapped market potential remains for agents that can improve the prognosis and overall survival compared with currently available agents.

Related Market Assessment Reports

Report
Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast (G7)
Treatment of multiple myeloma is complex. It involves a combination of proteasome inhibitors and/or immunomodulatory drugs (IMiDs) with chemotherapy. Treatment may also include cell-surface-…
Report
Multiple Myeloma – Unmet Need – Unmet Need – Third- and Fourth-Line Multiple Myeloma (US/EU)
The treatment of multiple myeloma is complex, often involving combinations of CD38-blocking monoclonal antibodies (MAbs), immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), chemotherapy,…
Report
Multiple Myeloma | Disease Landscape and Forecast | G7 | 2024
Treatment of multiple myeloma is complex. It involves a combination of proteasome inhibitors and/or immunomodulatory drugs (IMiDs) with chemotherapy. Treatment may also include cell-surface-…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome inhibitors and…
Report
Multiple Myeloma | Disease Landscape & Forecast | G7 | 2023
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment duration. The availability of premium-priced branded agents prescribed…